Sam’s Club offers 10 vaccines for cold-flu season
BENTONVILLE, Ark. — Sam’s Club is offering 10 immunizations for cold and flu season, the warehouse retailer said Monday.
The retailer said it would offer the immunizations at its 552 pharmacies. In partnership with Mollen Immunization Clinics, it’s also offering an expanded menu of immunizations by registered nurses through Nov. 15. The immunizations include flu, pneumonia, chickenpox, shingles, Tdap, human papillomavirus, MMR, meningitis, hepatitis A and hepatitis B.
"Under-vaccinated communities can face a greater risk of local outbreaks of disease, and the [Centers for Disease Control and Prevention’s] recommended vaccine schedule for adults is a great reference to ensure that our communities stay healthy," Sam’s Club SVP health and wellness Jill Turner-Mitchael said. "By offering the CDC’s recommended vaccines this year, Sam’s Club pharmacies continue to help our communities live healthy at a remarkable value."
Energizer introduces child-resistant packaging for coin lithium batteries
SHELTON, Conn. — Energizer said the new packaging for the brand’s coin lithium batteries meets the strict guidelines set by the Consumer Products Safety Commission for child-resistant packaging.
The company said the packaging overhaul was designed to reduce the occurrence of ingestions of coin-sized button batteries by children and the associated medical complications. Additionally, Energizer also has added easily understood icons on the front of the package to let parents know to keep the batteries away from small children, along with detailed warning copy advising of the danger of ingesting coin lithium batteries and how to get help if they are swallowed.
Energizer coin lithium batteries carry a suggested retail price of $6.99 per two-pack.
AstraZeneca, Broad Institute partner on antibiotic, antiviral drugs
CAMBRIDGE, Mass. — A drug maker and medical research institute will work together to identify new treatments for bacterial and viral infections.
AstraZeneca and the Broad Institute, owned jointly by Harvard University and MIT, announced Monday that they would collaborate for two years to develop medicines to treat severe infections, saying the identification of high-quality chemicals for the development of new drugs was a significant challenge. The two will use the Broad Institute’s collection of 100,000 chemicals known as diversity-oriented synthesis, or DOS compounds.
"We believe new and collaborative approaches between the private and public sectors will help speed the discovery and development of new treatments, particularly for antibiotic-resistant infections," AstraZeneca Infection Innovative Medicines Unit VP and head Manos Perros said. "We are very pleased to work hand-in-hand with the Broad Institute to combine our unique resources and strong histories in innovation, discovery and development to speed advancements in treatments for infections."